SDIX is a wholly owned subsidiary of OriGene Technologies, specializing in high quality, large-scale GMP antibody production in 3 locations in the U.S.; 2 sites in Delaware and one in Maine.
For over 25 years, SDIX has been a leading immuno-solutions company, developing results-oriented and innovative antibody-based solutions that enable customers, world-wide, to meet high performance diagnostic and commercialization objectives. All 3 sites are ISO 13485:2003 certified and the manufacturing site in Delaware is FDA and MHRA registered for the manufacture and export of class I IHC reagents and kits.
For IHC applications, over 40 CE-marked IVD reagents are manufactured and sold in the EU and US. Other products include critical reagents such as antibodies to Troponin I, Strep A, CRP, Apo A1, ApoB, Micro-albumin and Calibrators. SDIX also provides both polyclonal and monoclonal antibody development and production services, including long term supply of monoclonal antibodies for IVD and drug development applications as well as polyclonal antibody production in goat, rabbit and other species.
In the life science market, SDIX’s technology and capabilities are being used to help discover disease mechanisms, facilitate development of new drugs, and provide antibodies and assays utilized in the diagnosis of disease.